Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies

BACKGROUND: Dalbavancin is a lipoglycopepetide antibiotic with activity against gram positive pathogens recently approved for treatment of acute bacterial skin and skin structure infections. Pending the introduction of antimicrobial susceptibility tests, we examined the utility of vancomycin inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunne, Michael W, Sahm, Dan, Puttagunta, Sailaja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389583/
https://www.ncbi.nlm.nih.gov/pubmed/25885674
http://dx.doi.org/10.1186/s12941-015-0081-5
_version_ 1782365593454772224
author Dunne, Michael W
Sahm, Dan
Puttagunta, Sailaja
author_facet Dunne, Michael W
Sahm, Dan
Puttagunta, Sailaja
author_sort Dunne, Michael W
collection PubMed
description BACKGROUND: Dalbavancin is a lipoglycopepetide antibiotic with activity against gram positive pathogens recently approved for treatment of acute bacterial skin and skin structure infections. Pending the introduction of antimicrobial susceptibility tests, we examined the utility of vancomycin inhibitory concentrations to predict dalbavancin susceptibility in a panel of isolates obtained from phase 3 registration studies. FINDINGS: 99.6% of Staphylococcus aureus and 99.0% of beta-hemolytic streptococci which are susceptible to vancomycin will have an MIC at or below the US FDA susceptibility breakpoint for dalbavancin. CONCLUSION: Vancomycin should be considered as a surrogate for in vitro dalbavancin susceptibility testing.
format Online
Article
Text
id pubmed-4389583
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43895832015-04-09 Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies Dunne, Michael W Sahm, Dan Puttagunta, Sailaja Ann Clin Microbiol Antimicrob Short Report BACKGROUND: Dalbavancin is a lipoglycopepetide antibiotic with activity against gram positive pathogens recently approved for treatment of acute bacterial skin and skin structure infections. Pending the introduction of antimicrobial susceptibility tests, we examined the utility of vancomycin inhibitory concentrations to predict dalbavancin susceptibility in a panel of isolates obtained from phase 3 registration studies. FINDINGS: 99.6% of Staphylococcus aureus and 99.0% of beta-hemolytic streptococci which are susceptible to vancomycin will have an MIC at or below the US FDA susceptibility breakpoint for dalbavancin. CONCLUSION: Vancomycin should be considered as a surrogate for in vitro dalbavancin susceptibility testing. BioMed Central 2015-04-02 /pmc/articles/PMC4389583/ /pubmed/25885674 http://dx.doi.org/10.1186/s12941-015-0081-5 Text en © Dunne et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Short Report
Dunne, Michael W
Sahm, Dan
Puttagunta, Sailaja
Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
title Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
title_full Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
title_fullStr Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
title_full_unstemmed Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
title_short Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
title_sort use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the discover studies
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389583/
https://www.ncbi.nlm.nih.gov/pubmed/25885674
http://dx.doi.org/10.1186/s12941-015-0081-5
work_keys_str_mv AT dunnemichaelw useofvancomycinasasurrogatefordalbavancininvitrosusceptibilitytestingresultsfromthediscoverstudies
AT sahmdan useofvancomycinasasurrogatefordalbavancininvitrosusceptibilitytestingresultsfromthediscoverstudies
AT puttaguntasailaja useofvancomycinasasurrogatefordalbavancininvitrosusceptibilitytestingresultsfromthediscoverstudies

Ejemplares similares